Biguanide mechanism discovered

Researchers have discovered a novel mechanism by which biguanides exert their glucose-lowering effect, potentially leading to new therapeutic approaches to the treatment of diabetes and insulin resistance.

"We have shown that it is through an elevation in intracellular AMP [adenosine monophosphate] that metformin substantially abrogates the activation of adenylate cyclase by glucagon. This results in a reduction in the phosphorylation of key substrates for maintaining hepatic glucose output," report Morris Birnbaum (University of Pennsylvania, Philadelphia, USA) and colleagues.

Some experts previously believed that metformin reduces glucose synthesis through activation of AMP-activated protein kinase (AMPK), but this has recently been challenged by studies showing that mice without AMPK still respond to metformin, explain the authors.

In primary mouse hepatocytes, the team found that 24-hour exposure to phenformin at concentrations of 10 µM or greater significantly reduced glucagon-stimulated increases in cyclic AMP (cAMP) levels. Similarly, exposure to metformin at 125 µM also inhibited cAMP accumulation.

Exposure to each of the drugs also resulted in significant increases in intracellular levels of AMP.

The team explains that under usual circumstances, the binding of glucagon to its receptor on hepatocyte membranes activates the enzyme adenylate cyclase, which stimulates the synthesis of cyclic AMP (cAMP) from adenosine triphosphate (ATP) and the activity of protein kinase. Protein kinase activity (PKA) results in the phosphorylation of protein targets, which then work together to increase hepatic glucose output.

However, as metformin and phenformin blocked glucagon-induced cAMP production at concentrations that correlated well with their effects on AMP levels, the authors tested whether AMP could directly inhibit adenylate cyclase.

As reported in Nature, AMP inhibited glucagon-stimulated adenylate cyclase activity when ATP was present at 160 µM (typical assay conditions) as well as at the more physiological ATP concentration of 1.28 mM.

Furthermore, in mice injected with metformin, the glucagon-dependent increases in hepatic cAMP were reduced, as were PKA and the phosphorylation of PKA substrates, demonstrating the in vivo blockade of this pathway by the biguanides, says the team.

"Understanding the mechanism by which the drug metformin reduces hepatic glucose is of considerable importance," write Birnbaum et al.

The findings suggest that adenylate cyclase might represent a novel target for the development of treatments for insulin resistance and Type 2 diabetes, they conclude.

Licensed from medwireNews with permission from Springer Healthcare Ltd. ©Springer Healthcare Ltd. All rights reserved. Neither of these parties endorse or recommend any commercial products, services, or equipment.

Sally Robertson

Written by

Sally Robertson

Sally first developed an interest in medical communications when she took on the role of Journal Development Editor for BioMed Central (BMC), after having graduated with a degree in biomedical science from Greenwich University.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Robertson, Sally. (2018, August 23). Biguanide mechanism discovered. News-Medical. Retrieved on November 12, 2024 from https://www.news-medical.net/news/20130114/Biguanide-mechanism-discovered.aspx.

  • MLA

    Robertson, Sally. "Biguanide mechanism discovered". News-Medical. 12 November 2024. <https://www.news-medical.net/news/20130114/Biguanide-mechanism-discovered.aspx>.

  • Chicago

    Robertson, Sally. "Biguanide mechanism discovered". News-Medical. https://www.news-medical.net/news/20130114/Biguanide-mechanism-discovered.aspx. (accessed November 12, 2024).

  • Harvard

    Robertson, Sally. 2018. Biguanide mechanism discovered. News-Medical, viewed 12 November 2024, https://www.news-medical.net/news/20130114/Biguanide-mechanism-discovered.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Lithuanian scientists develop non-invasive device to improve blood circulation